# Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

> **NCT05898256** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Guangxi Medical University** · enrollment: 20 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma
- Immune Checkpoint Inhibitors

## Interventions

- **DRUG:** Cadonilimab
- **DRUG:** Gemcitabine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05898256
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2024-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05898256

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05898256, "Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05898256. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*